Mohammadhassan Mirbolouk1, Sina Kianoush1, Zeina Dardari2, Michael D Miedema3, Leslee J Shaw4, John A Rumberger5, Daniel S Berman6, Matthew J Budoff7, Alan Rozanski8, Mouaz H Al-Mallah9, John W McEvoy2, Khurram Nasir10, Michael J Blaha11. 1. Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States; Yale University School of Medicine, New Haven, CT, United States. 2. Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States. 3. Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Minneapolis, MN, United States. 4. Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States. 5. Princeton Longevity Center, Princeton, NJ, United States. 6. Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, CA, United States. 7. Department of Medicine, Harbor UCLA Medical Center, Los Angeles, CA, United States. 8. Department of Medicine, St. Luke's Roosevelt Hospital, New York, NY, United States. 9. King Abdul-Aziz Cardiac Center, Riyadh, Saudi Arabia. 10. Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States; Center for Outcomes Research and Evaluation (CORE), Section of Cardiovascular Medicine, Yale University School of Medicine, United States. 11. Johns Hopkins Ciccarone Center for Prevention of Heart Disease, Baltimore, MD, United States. Electronic address: mblaha1@jhmi.edu.
Abstract
BACKGROUND AND AIMS: Cardiovascular disease (CVD) and cancer are the two leading causes of death in smokers. Lung cancer screening is recommended in a large proportion of smokers. We examined the implication of coronary artery calcium (CAC) score (quantitative and qualitative) for cardiovascular disease (CVD), coronary heart disease (CHD), and cancer mortality risk prediction among current smokers. METHODS: We included current smokers without known heart disease from the CAC Consortium. Cox regression (for all-cause mortality) and Fine-and-Gray competing-risk regression (for CVD, CHD, and cancer mortality) models, adjusted for traditional CVD risk factors, were used to assess the association between CAC and each mortality outcome, with CAC as a continuous (log2-transformed) or categorical variable (CAC = 0, CAC = 1-99, CAC = 100-399, and CAC ≥400). We used number of vessels with CAC as a surrogate for the qualitative measure of CAC and mortality outcomes. Analyses were repeated for lung cancer screening-eligible population (defined as ever smokers with >30 pack years smoking history) (n = 1,149). Hazard ratios (HR) for all-cause mortality and Subdistribution HRs (sHR) with 95% confidence intervals (CI) were reported. RESULTS: Over a median of 11.9 years (25th-75th percentile: 10.2-13.3) of follow-up, of 5,147 current smokers (mean age 52.5 ± 9.4, 32.4% women) 337 died (102 of CVD, 54 of CHD, and 123 of cancer). A doubling of CAC score was associated with increased HRs of all-cause mortality (1.10 (1.06-1.14)), and sHRs for CVD (1.15 (1.07-1.24)), CHD (1.26 (1.11-1.42)) and cancer mortality (1.06 (1.00-1.13)). Those with CAC ≥400 had increased sHR of CVD (3.55 (1.70-7.41)), CHD (8.80 (2.41-32.10)), and cancer mortality (1.85 (1.07-3.22)), compared with those with CAC = 0. A diffuse CAC pattern significantly increased the risk of all-cause, CVD, and CHD mortality among smokers. Results were consistent for the lung cancer screening-eligible population. CONCLUSIONS: Qualitative and quantitative CAC scores can prognosticate risk of all-cause, CVD, CHD, and cancer mortality beyond traditional risk factors among all smokers as well as those eligible for lung cancer screening.
BACKGROUND AND AIMS: Cardiovascular disease (CVD) and cancer are the two leading causes of death in smokers. Lung cancer screening is recommended in a large proportion of smokers. We examined the implication of coronary artery calcium (CAC) score (quantitative and qualitative) for cardiovascular disease (CVD), coronary heart disease (CHD), and cancer mortality risk prediction among current smokers. METHODS: We included current smokers without known heart disease from the CAC Consortium. Cox regression (for all-cause mortality) and Fine-and-Gray competing-risk regression (for CVD, CHD, and cancer mortality) models, adjusted for traditional CVD risk factors, were used to assess the association between CAC and each mortality outcome, with CAC as a continuous (log2-transformed) or categorical variable (CAC = 0, CAC = 1-99, CAC = 100-399, and CAC ≥400). We used number of vessels with CAC as a surrogate for the qualitative measure of CAC and mortality outcomes. Analyses were repeated for lung cancer screening-eligible population (defined as ever smokers with >30 pack years smoking history) (n = 1,149). Hazard ratios (HR) for all-cause mortality and Subdistribution HRs (sHR) with 95% confidence intervals (CI) were reported. RESULTS: Over a median of 11.9 years (25th-75th percentile: 10.2-13.3) of follow-up, of 5,147 current smokers (mean age 52.5 ± 9.4, 32.4% women) 337 died (102 of CVD, 54 of CHD, and 123 of cancer). A doubling of CAC score was associated with increased HRs of all-cause mortality (1.10 (1.06-1.14)), and sHRs for CVD (1.15 (1.07-1.24)), CHD (1.26 (1.11-1.42)) and cancer mortality (1.06 (1.00-1.13)). Those with CAC ≥400 had increased sHR of CVD (3.55 (1.70-7.41)), CHD (8.80 (2.41-32.10)), and cancer mortality (1.85 (1.07-3.22)), compared with those with CAC = 0. A diffuse CAC pattern significantly increased the risk of all-cause, CVD, and CHDmortality among smokers. Results were consistent for the lung cancer screening-eligible population. CONCLUSIONS: Qualitative and quantitative CAC scores can prognosticate risk of all-cause, CVD, CHD, and cancer mortality beyond traditional risk factors among all smokers as well as those eligible for lung cancer screening.
Authors: Siegfried Adelhoefer; S M Iftekhar Uddin; Albert D Osei; Olufunmilayo H Obisesan; Michael J Blaha; Omar Dzaye Journal: Radiol Cardiothorac Imaging Date: 2020-12-17
Authors: Omar Dzaye; Philipp Berning; Zeina A Dardari; Daniel S Berman; Matthew J Budoff; Michael D Miedema; Khurram Nasir; Alan Rozanski; John A Rumberger; Leslee J Shaw; Martin Bødtker Mortensen; Seamus P Whelton; Michael J Blaha Journal: Atherosclerosis Date: 2021-10-18 Impact factor: 5.162
Authors: Cilie C van 't Klooster; Yolanda van der Graaf; Hendrik M Nathoe; Michiel L Bots; Gert J de Borst; Frank L J Visseren; Tim Leiner Journal: Int J Cardiovasc Imaging Date: 2021-02-12 Impact factor: 2.357